Bibliography
- EGLEN R, CHOPPIN A, DILLON MP, HEDGE S: Muscarinic receptor ligands and their therapeutic potential. Curr. Opin. Chem. Biol. (1999) 3(3):426–432.
- ••Excellent review of the field
- NORMAN P, GRAUL A, RABASSEDA X, CASTANER J: Tiotropium bromide. Drugs of the Future (2000) 25:693–699.
- CLEMETT D, JARVIS B: Tolterodine a review of its use in the treatment of overactive bladder. Drugs Ageing. (2001) 18(4):277–304.
- ALABASTER VA: Discovery & development of selective M3 antagonists for clinical use. L. Sci. (1997) 60(13-14):1053–1060
- •Covers the pre-clinical pharmacology of Pfizer's compounds.
- WALLIS RM, NAPIER CM: Muscarinic antagonists in development for disorders of smooth muscle function. L. Sci. (1999):64(6–7)395-401
- •Principally summarises activity of darifenacin.
- MEALY M, CASTANER J: YM-905. Treatment of urinary incontinence muscarinic M3 antagonist. Drugs of the Future (1999) 24(8):871–874.
- WITEK T J, DISSE B: Inhaled anticholinergic therapy: applied pharmacology and interesting developments Curr. Opin. Investigational Drugs (2001) 2(1):53–58
- •Useful discussion of the requirements for good efficacy.
- MITSUYA M, MASE T, TSUCHIYA Yet al.: J-104129, a novel muscarinic M3 receptor antagonist with high selectivity for M3 over M2 receptors. Bioorg-. Med. Chem. (1999) 7(11):2555–2567.
- MITSUYA M, KOBAYASHI K, KAWAKAMI K et al.: A potent, long-acting, orally active (2R)-2-[(1R)-3,3-difluorocyclopentyl] -2-hydroxy-2- phenylacetamide: a novel muscarinic M3 receptor antagonist with high selectivity for M3 over M2 receptors. J. Med. Chem. (2000) 43 (26):5017–5029.
- HIROSE H, AOKI I, KIMURA T et aL: Pharmacological properties of (2R)-N41-(6- aminopyridin-2-ylmethyl)piperidin-4-yll -2- R1R)-3,3-difluorocyclopentyll-2-hydroxy-2-phenylacetamide. J. PharmacoL Exp. (2001) 297(2):790–797.
- SAGARA Y, SAGARA T, NOGUCHI K, OHTAKE N: First M3 antagonist (N-cyclohexylmethylpiperidinyltriphenylpropio amide: CPTP) with a high selectivity over the other receptor subtypes. 222nd ACS National Meeting. (2001) MEDI 196.
- ••Highlights the selectivity and potency of this class of compounds.